Loading...
XSHG
688366
Market cap1.44bUSD
Dec 05, Last price  
48.86
1D
0.66%
1Q
-10.59%
IPO
-62.62%
Name

Shanghai Haohai Biological Technology Co Ltd

Chart & Performance

D1W1MN
XSHG:688366 chart
P/E
P/S
EPS
1.02
Div Yield, %
2.28%
Shrs. gr., 5y
7.42%
Rev. gr., 5y
10.93%
Revenues
2.68b
+1.70%
303,065,000401,088,000515,940,000663,917,000851,157,0001,344,856,0001,545,824,0001,595,498,0001,324,427,0001,750,116,0002,103,438,0002,634,910,0002,679,667,000
Net income
420m
+1.04%
113,942,000141,521,000183,582,000273,474,000305,052,000372,415,000414,540,000370,779,000230,072,000352,234,000180,470,000416,121,000420,447,000
CFO
649m
+2.23%
118,420,000146,906,000141,993,000268,511,000254,485,000343,059,000391,284,000348,911,000262,073,000342,286,000231,296,000634,450,000648,572,000
Dividend
Oct 10, 20240.4 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, the United States, the United Kingdom, and internationally. It offers ophthalmology products comprising intraocular lens, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, scalpels, etc.; orthopedics products, such as sodium hyaluronate injection and medical chitosan; wound repair products, including recombinant human epidermal growth factor for the treatment of burn wound, residual wound, donor site posttraumatic wound, and fresh or old wound of chronic ulcer; anti-adhesion materials comprising medical sodium hyaluronate gel and medical chitosan; and hemostatic materials, such as collagen sponge and porcine fibrin sealants. The company also provides medical aesthetics products comprising Matrifill, a first-generation HA dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; and radio frequency devices and laser equipment. In addition, it is involved in research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services; and investment and trading business. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.
IPO date
Apr 30, 2015
Employees
2,123
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT